中新网广州9月27日电(记者 王华)中华医学研究会肝病委员会推出“肝病宝典、与你同行”大型护肝公益活动27日在广州启动。活动共筹资500万元，将为1000名肝病患者免费提供抗病毒药品。

Beijing on September 27 - guangzhou(Reporter wang hua)The medical research council launched liver disease"Liver disease bible/To be with you"Large protect liver public benefit activities 27 in guangzhou start.Activities were raised funds of 5 million yuan,For the 1000 patients with liver diseases will provide free antiviral drugs.

　　国内首条科普、援助热线4009991700也同时启用。

The first popular science/Assistance hotline at 4009991700 also enable.

　　中华医学研究会肝病委员会一项调查显示，城市乙肝患者接受抗病毒治疗的占60%，而农村乙肝患者仅占15%。调査还显示，83%的乙肝患者存在不同程度的肝纤维化，而同时进行抗纤维化治疗的不足10%。

The iom committee of liver disease, according to a poll,City of hepatitis b patients on antiiral therapy accounted for 60%,While the rural hepatitis b patients accounted for only 15%.Adjustable 査 also showed,83% of the patients with chronic hepatitis b there exists different degree of liver fibrosis,At the same time for anti fibrosis treatment of less than 10%.

　　中华医学研究会肝病委员会副主任委员王洪剑认为，乙肝病毒持续复制是造成肝硬化、肝癌的罪魁祸首，抗病毒治疗是遏制乙肝患者病情进展的关键，抗纤维化治疗越早越好，两者联合治疗有望取得临床上的高效与低复发。

The Chinese medicine research institute liver disease committee member, deputy director of the WangHongJian think,Hepatitis b virus continues to copy is cause liver cirrhosis/Liver cancer culprit,Antiviral treatment is to contain the hepatitis b patients progress key,Anti fibrosis treatment the sooner, the better,Both combination therapy is expected to obtain the clinical efficiency and low recurrence.

　　王洪剑称，许多乙肝患者认为抗病毒治疗无止境，对抗病毒治疗缺乏信心和耐心，害怕长期治疗以及药物耐药等。 其实，3-5年规范治疗并不意味病人都要终生服用。肝功能恢复正常、病毒复制指标转阴再巩固一年可考虑停药。

WangHongJian says,Many patients with chronic hepatitis b antiviral treatment that endless,Against the virus treatment lack of confidence and patience,Afraid of long-term therapy and drug resistance, etc. In fact,3-5 years of standardized treatment does not mean that the patient will take a lifetime.Liver function returned to normal/Virus replication index, shade to consolidate a year can consider withdrawal.

　　王洪剑表示，每月四、五百元至上千元不等的医药费，让部分乙肝患者难以承受，乙肝及相关疾病是许多家庭因病致贫、因病返贫的重要因素。此次公益活动旨在了解患者无法长期坚持规范抗病毒治疗的原因，帮助患者远离虛假乙肝广告。

WangHongJian said,Monthly four/Five hundred yuan to thousands of dollars of medical expenses,Let the part of second liver patient is difficult to bear,Hepatitis b and related diseases are many families become financially-difficult/The important factor of poverty due to illness.The public benefit activities is to understand the patients can't insist for a long time to regulate the cause of antiviral treatment,To help patients with hepatitis b from false advertising.

　　此次活动将针对中国2000万适合抗病毒治疗的乙肝、肝硬化患者，经报名筛选进行免费提供药品治疗，但乙肝病毒携带者不在受助之列。据悉，此次公益活动为期一年，将为1000名适合抗病毒的乙肝、肝硬化患者免费提供一年的抗病毒药物，每位患者年节省药费5000元左右。

This activity will be in China for 20 million hepatitis b antiviral treatment/Liver cirrhosis patients,The application screening to provide free drug treatment,But the hepatitis b virus is not among the recipients.It is reported,The public welfare activities for the period of one year,For 1000 is suitable for antiviral hepatitis b/Patients with cirrhosis provide free one year of antiviral drugs,Each patient years save expenses for medicine 5000 yuan or so.